What is HC Wainwright's Estimate for Entera Bio Q1 Earnings?

Key Points

• HC Wainwright analyst R. Selvaraju forecasts Entera Bio will report Q1 2027 EPS of ($0.13), maintains a Buy rating and a $9.00 target, and models Q2–Q4 EPS of ($0.13)/($0.15)/($0.16) with FY2027 EPS of ($0.57).
• Analyst coverage is mixed — one Buy and one Sell produce a consensus Hold and an average target of $9.00 — while the stock trades around $1.15 (market cap ≈ $53.6M) after a recent 2.7% uptick.
• Entera Bio beat the prior quarter with EPS of ($0.07)

Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Entera Bio in a research report issued to clients and investors on Monday, April 27th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.13) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Entera Bio's current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Entera Bio's Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.57) EPS.

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Entera Bio in a research report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $9.00.

Entera Bio Trading Up 2.7%

ENTX opened at $1.15 on Tuesday. The stock has a market cap of $53.61 million, a PE ratio of -4.42 and a beta of 1.54. Entera Bio has a 1 year low of $0.91 and a 1 year high of $3.22. The stock's 50 day simple moving average is $1.26 and its 200-day simple moving average is $1.78.

Entera Bio (NASDAQ:ENTX - Get Free Report) last released its quarterly earnings data on Friday, March 27th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02.

Institutional Trading of Entera Bio

A number of large investors have recently bought and sold shares of ENTX. Superstring Capital Management LP bought a new stake in Entera Bio in the fourth quarter valued at $33,000. Citadel Advisors LLC grew its position in Entera Bio by 243.0% in the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company's stock valued at $77,000 after acquiring an additional 28,322 shares during the period. HighTower Advisors LLC grew its position in Entera Bio by 137.8% in the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company's stock valued at $84,000 after acquiring an additional 25,000 shares during the period. Jane Street Group LLC grew its position in Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company's stock valued at $144,000 after acquiring an additional 43,536 shares during the period. Finally, Renaissance Technologies LLC grew its position in Entera Bio by 22.2% in the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company's stock valued at $210,000 after acquiring an additional 19,601 shares during the period. 14.11% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Geno J. Germano purchased 20,000 shares of the stock in a transaction on Monday, March 9th. The shares were purchased at an average cost of $1.30 per share, for a total transaction of $26,000.00. Following the completion of the transaction, the director directly owned 40,000 shares of the company's stock, valued at approximately $52,000. The trade was a 100.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders acquired 58,000 shares of company stock valued at $72,620 in the last quarter. Corporate insiders own 10.38% of the company's stock.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company's lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.